Trial Profile

A phase I/II clinical trial of MDNA113

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 25 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MDNA 113 (Primary)
Indications Solid tumours
Focus Adverse reactions; First in man

Most Recent Events

13 Feb 2026 According to the Medicenna Therapeutics media release, company plan to file an IND for MDNA113 and arrange an End of Phase 1 meeting with the FDA for a potential registrational trial with MDNA11.
15 Jan 2026 According to the Medicenna Therapeutics media release, IND submission for MDNA113 is expected in H2 2026 and initiating a Phase 1/2a trial by Q4 2026.
12 Dec 2025 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com